ATAI
AtaiBeckley Inc.
Price Chart
No historical data available
Latest Quote
$7.35
+0.00 (+0.00%)
Current Price
| Previous Close | $7.35 |
| Day High | $7.37 |
| Day Low | $7.30 |
Stock Information
| Shares Outstanding | 370.86M |
| Total Debt | $4.29M |
| Cash Equivalents | $225.81M |
| Revenue | $4.47M |
| Net Income | $-668.19M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $2.73B |
| EPS (TTM) | $-2.79 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $2.50B |
| Sales | $4.47M |
| Income | $-668.19M |
| Book/sh | $0.48 |
| Cash/sh | $0.61 |
| Employees | 99 |
Financial Ratios
| Quick Ratio | 8.29 |
| Current Ratio | 8.58 |
| Debt/Eq | 2.43 |
Returns & Margins
| ROA | -39.03% |
| ROE | -417.21% |
| Operating Margin | -2590.43% |
Ownership
| Insider Ownership | 2.18% |
| Institutional Ownership | 52.30% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -15.31 |
| P/S | 609.54 |
| P/B | 15.38 |
Analyst Data
| Recommendation | hold |
| Target Price | $8.12 |
Technical Indicators
| Shares Float | 308.41M |
| Short Float | 6.11% |
| Short Ratio | 2.84 |
| Volatility | 1.55 |
Performance History
| YTD | +0.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
No history data available. Data will be fetched automatically.
About AtaiBeckley Inc.
AtaiBeckley Inc., a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of mental health treatments. The company develops rapid-acting and durable therapies for conditions with limited treatment options. Its pipeline includes BPL-003 (mebufotenin benzoate), an intranasal formulation in Phase 2 and 3 clinical studies for treatment-resistant depression and alcohol use disorder; ELE-101, a serotonergic psychedelic for major depressive disorder; and RL-007, an orally bioavailable pro-cognitive neuromodulator in Phase 2b trial for cognitive impairment associated with schizophrenia. The company's pipeline also comprises VLS-01, an oral transmucosal film formulation of N, N-Dimethyltryptamine in Phase 2 clinical study for treatment-resistant depression; EMP-01, an oral formulation of the R-enantiomer of 3,4-methylenedioxy-methamphetamine in Phase 2 clinical study for social anxiety disorder; and EGX-A and EGX-B, non-hallucinogenic 5-HT2A receptor agonists for treatment-resistant depression. Additionally, it offers COMP360, a psilocybin therapy; and GRX-917, a treatment for anxiety, depression, and various neurological disorders. The company has additional operations in Germany and Canada. AtaiBeckley Inc. was formerly known as Atai Beckley N.V. and changed its name to AtaiBeckley Inc. in December 2025. AtaiBeckley Inc. was founded in 2018 and is based in New York, New York. AtaiBeckley Inc. operates as a subsidiary of Eli Lilly and Company.
đ° Latest News
No news articles available at the moment. Check back later for updates on ATAI.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Total Revenue | $4,089,000 | $308,000 | $314,000 | $233,000 |
| Operating Revenue | $4,089,000 | $308,000 | $314,000 | $233,000 |
| Expenses | ||||
| Interest Expense | $1,162,000 | $3,124,000 | $2,656,000 | $923,000 |
| Total Expenses | $117,436,000 | $102,474,000 | $123,340,000 | $144,663,000 |
| Other Income Expense | $-546,818,000 | $-43,893,000 | $84,549,000 | $9,623,000 |
| Other Non Operating Income Expenses | $-2,589,000 | $5,898,000 | $-189,000 | $-489,000 |
| Net Non Operating Interest Income Expense | $316,000 | $-2,346,000 | $-809,000 | $-375,000 |
| Interest Expense Non Operating | $1,162,000 | $3,124,000 | $2,656,000 | $923,000 |
| Operating Expense | $117,436,000 | $102,474,000 | $123,340,000 | $144,663,000 |
| General And Administrative Expense | $65,088,000 | $47,544,000 | $63,582,000 | $70,350,000 |
| Other Operating Expenses | - | $-525,000 | $-2,445,000 | - |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-660,047,000 | $-149,269,000 | $-40,224,000 | $-152,385,000 |
| Net Interest Income | $316,000 | $-2,346,000 | $-809,000 | $-375,000 |
| Interest Income | $1,478,000 | $778,000 | $1,847,000 | $548,000 |
| Normalized Income | $-230,106,090 | $-99,597,441 | $-107,167,020 | $-160,373,480 |
| Net Income From Continuing And Discontinued Operation | $-660,047,000 | $-149,269,000 | $-40,224,000 | $-152,385,000 |
| Total Operating Income As Reported | $-644,061,000 | $-102,691,000 | $-125,471,000 | $-144,787,000 |
| Net Income Common Stockholders | $-660,047,000 | $-149,269,000 | $-40,224,000 | $-152,385,000 |
| Net Income | $-660,047,000 | $-149,269,000 | $-40,224,000 | $-152,385,000 |
| Net Income Including Noncontrolling Interests | $-660,147,000 | $-150,049,000 | $-43,895,000 | $-157,417,000 |
| Net Income Continuous Operations | $-660,147,000 | $-150,049,000 | $-43,895,000 | $-157,417,000 |
| Earnings From Equity Interest Net Of Tax | $0 | $-2,000,000 | $-3,593,000 | $-16,006,000 |
| Pretax Income | $-659,849,000 | $-148,405,000 | $-39,286,000 | $-135,182,000 |
| Special Income Charges | $-525,515,000 | $1,166,000 | $-951,000 | $1,127,000 |
| Interest Income Non Operating | $1,478,000 | $778,000 | $1,847,000 | $548,000 |
| Operating Income | $-113,347,000 | $-102,166,000 | $-123,026,000 | $-144,430,000 |
| Earnings From Equity Interest | - | - | - | - |
| Per Share | ||||
| Diluted EPS | $-2.91 | $-0.93 | $-0.25 | $-0.98 |
| Basic EPS | $-2.91 | $-0.93 | $-0.25 | $-0.98 |
| Other | ||||
| Tax Effect Of Unusual Items | $-114,288,090 | $-119,441 | $17,794,980 | $2,123,520 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-113,446,000 | $-95,017,000 | $-121,049,000 | $-144,203,000 |
| Total Unusual Items | $-544,229,000 | $-49,791,000 | $84,738,000 | $10,112,000 |
| Total Unusual Items Excluding Goodwill | $-544,229,000 | $-49,791,000 | $84,738,000 | $10,112,000 |
| Reconciled Depreciation | $1,012,000 | $473,000 | $319,000 | $168,000 |
| EBITDA (Bullshit earnings) | $-657,675,000 | $-144,808,000 | $-36,311,000 | $-134,091,000 |
| EBIT | $-658,687,000 | $-145,281,000 | $-36,630,000 | $-134,259,000 |
| Diluted Average Shares | $226,532,786 | $160,159,983 | $158,833,785 | $155,719,585 |
| Basic Average Shares | $226,532,786 | $160,159,983 | $158,833,785 | $155,719,585 |
| Diluted NI Availto Com Stockholders | $-660,047,000 | $-149,269,000 | $-40,224,000 | $-152,385,000 |
| Minority Interests | $100,000 | $780,000 | $3,671,000 | $5,032,000 |
| Tax Provision | $298,000 | $-356,000 | $1,016,000 | $6,229,000 |
| Gain On Sale Of Ppe | $-692,000 | $0 | - | - |
| Gain On Sale Of Business | $0 | $1,166,000 | $60,000 | $1,484,000 |
| Other Special Charges | $524,823,000 | - | - | $357,000 |
| Gain On Sale Of Security | $-18,714,000 | $-50,957,000 | $85,689,000 | $8,985,000 |
| Other Taxes | $-714,000 | $-525,000 | - | - |
| Research And Development | $53,062,000 | $55,455,000 | $62,203,000 | $74,313,000 |
| Selling General And Administration | $65,088,000 | $47,544,000 | $63,582,000 | $70,350,000 |
| Other Gand A | $65,088,000 | $47,544,000 | $63,582,000 | $70,350,000 |
| Write Off | - | $0 | $1,011,000 | $0 |
| Restructuring And Mergern Acquisition | - | $-5,567,000 | $0 | $-2,959,000 |
Fetched: 2026-08-18
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $218,692,000 | $112,720,000 | $241,190,000 | $260,740,000 |
| Total Assets | $292,723,000 | $159,387,000 | $293,478,000 | $305,441,000 |
| Total Non Current Assets | $17,039,000 | $79,262,000 | $107,886,000 | $18,296,000 |
| Other Non Current Assets | $1,110,000 | $850,000 | $948,000 | $3,125,000 |
| Investmentin Financial Assets | $0 | $42,079,000 | $1,838,000 | $6,755,000 |
| Goodwill And Other Intangible Assets | $3,182,000 | $3,577,000 | $1,772,000 | - |
| Other Intangible Assets | $2,851,000 | $3,246,000 | $1,772,000 | - |
| Current Assets | $275,684,000 | $80,125,000 | $185,592,000 | $287,145,000 |
| Other Current Assets | $946,000 | $421,000 | $846,000 | $1,745,000 |
| Restricted Cash | $0 | $10,000,000 | $0 | - |
| Prepaid Assets | $4,271,000 | $5,672,000 | $3,232,000 | $6,660,000 |
| Receivables | $14,427,000 | $1,702,000 | $2,257,000 | $5,631,000 |
| Taxes Receivable | $13,135,000 | $1,348,000 | $1,752,000 | $5,631,000 |
| Notes Receivable | $625,000 | $0 | $505,000 | $0 |
| Accounts Receivable | $667,000 | $354,000 | - | - |
| Cash Cash Equivalents And Short Term Investments | $256,040,000 | $62,330,000 | $179,257,000 | $273,109,000 |
| Cash And Cash Equivalents | $85,300,000 | $17,505,000 | $45,034,000 | $190,613,000 |
| Non Current Note Receivables | - | $0 | $11,299,000 | $7,262,000 |
| Non Current Deferred Assets | - | - | - | - |
| Debt | ||||
| Total Debt | $2,072,000 | $24,706,000 | $19,142,000 | $15,341,000 |
| Long Term Debt And Capital Lease Obligation | $1,801,000 | $14,865,000 | $18,867,000 | $15,161,000 |
| Current Debt And Capital Lease Obligation | $271,000 | $9,841,000 | $275,000 | $180,000 |
| Net Debt | - | $5,992,000 | - | - |
| Long Term Debt | - | $14,133,000 | $17,877,000 | $15,117,000 |
| Current Debt | - | $9,364,000 | - | - |
| Other Current Borrowings | - | $9,364,000 | - | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $70,722,000 | $42,833,000 | $49,162,000 | $39,675,000 |
| Total Non Current Liabilities Net Minority Interest | $47,243,000 | $17,882,000 | $29,042,000 | $19,778,000 |
| Other Non Current Liabilities | $1,063,000 | $3,017,000 | $10,175,000 | $4,617,000 |
| Derivative Product Liabilities | $44,379,000 | $0 | - | - |
| Current Liabilities | $23,479,000 | $24,951,000 | $20,120,000 | $19,897,000 |
| Other Current Liabilities | $3,144,000 | $2,463,000 | $1,101,000 | $718,000 |
| Current Deferred Liabilities | $1,524,000 | $721,000 | - | - |
| Payables And Accrued Expenses | $18,540,000 | $11,926,000 | $18,744,000 | $18,999,000 |
| Payables | $4,926,000 | $2,804,000 | $5,304,000 | $4,623,000 |
| Total Tax Payable | $20,000 | $188,000 | $715,000 | $2,224,000 |
| Accounts Payable | $4,906,000 | $2,616,000 | $4,589,000 | $2,399,000 |
| Equity | ||||
| Common Stock Equity | $221,874,000 | $116,297,000 | $242,962,000 | $260,740,000 |
| Total Equity Gross Minority Interest | $222,001,000 | $116,554,000 | $244,316,000 | $265,766,000 |
| Stockholders Equity | $221,874,000 | $116,297,000 | $242,962,000 | $260,740,000 |
| Gains Losses Not Affecting Retained Earnings | $-20,926,000 | $-18,466,000 | $-19,460,000 | $-21,702,000 |
| Other Equity Adjustments | $-20,926,000 | $-18,466,000 | $-19,460,000 | $-21,702,000 |
| Retained Earnings | $-1,360,254,000 | $-700,207,000 | $-550,938,000 | $-510,188,000 |
| Other Equity Interest | - | - | - | $-24,000 |
| Long Term Equity Investment | - | - | - | $0 |
| Investments In Other Ventures Under Equity Method | - | - | - | - |
| Other | ||||
| Ordinary Shares Number | $363,280,522 | $167,959,752 | $166,026,396 | $165,935,914 |
| Share Issued | $363,280,522 | $167,959,752 | $166,026,396 | $165,935,914 |
| Tangible Book Value | $218,692,000 | $112,720,000 | $241,190,000 | $260,740,000 |
| Invested Capital | $221,874,000 | $139,794,000 | $260,839,000 | $275,857,000 |
| Working Capital | $252,205,000 | $55,174,000 | $165,472,000 | $267,248,000 |
| Capital Lease Obligations | $2,072,000 | $1,209,000 | $1,265,000 | $224,000 |
| Total Capitalization | $221,874,000 | $130,430,000 | $260,839,000 | $275,857,000 |
| Minority Interest | $127,000 | $257,000 | $1,354,000 | $5,026,000 |
| Additional Paid In Capital | $1,599,421,000 | $816,185,000 | $794,787,000 | $774,092,000 |
| Capital Stock | $3,633,000 | $18,785,000 | $18,573,000 | $18,562,000 |
| Common Stock | $3,633,000 | $18,785,000 | $18,573,000 | $18,562,000 |
| Preferred Stock | $0 | $0 | - | - |
| Long Term Capital Lease Obligation | $1,801,000 | $732,000 | $990,000 | $44,000 |
| Current Deferred Revenue | $1,524,000 | $721,000 | - | - |
| Current Capital Lease Obligation | $271,000 | $477,000 | $275,000 | $180,000 |
| Current Accrued Expenses | $13,614,000 | $9,122,000 | $13,440,000 | $14,376,000 |
| Investments And Advances | $8,735,000 | $70,966,000 | $91,663,000 | $6,755,000 |
| Other Investments | $8,735,000 | $28,887,000 | $89,825,000 | $0 |
| Goodwill | $331,000 | $331,000 | $0 | - |
| Net PPE | $4,012,000 | $3,869,000 | $2,204,000 | $1,154,000 |
| Accumulated Depreciation | $-405,000 | $-398,000 | $-153,000 | - |
| Gross PPE | $4,417,000 | $4,267,000 | $2,357,000 | $1,154,000 |
| Leases | $564,000 | $0 | - | - |
| Other Properties | $3,580,000 | $2,906,000 | $1,223,000 | $1,154,000 |
| Machinery Furniture Equipment | $273,000 | $1,361,000 | $1,134,000 | - |
| Properties | $0 | $0 | - | - |
| Other Short Term Investments | $170,740,000 | $44,825,000 | $134,223,000 | $82,496,000 |
| Available For Sale Securities | - | $42,079,000 | $1,838,000 | $6,755,000 |
| Treasury Shares Number | - | - | $0 | - |
Fetched: 2026-08-18
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $-113,543,000 | $-82,532,000 | $-84,708,000 | $-105,491,000 |
| Operating Activities | ||||
| Operating Cash Flow | $-102,675,000 | $-82,437,000 | $-84,118,000 | $-104,467,000 |
| Cash Flow From Continuing Operating Activities | $-102,675,000 | $-82,437,000 | $-84,118,000 | $-104,467,000 |
| Operating Gains Losses | $521,879,000 | $652,000 | $4,332,000 | $9,572,000 |
| Investing Activities | ||||
| Capital Expenditure | $-10,868,000 | $-95,000 | $-590,000 | $-1,024,000 |
| Investing Cash Flow | $-109,127,000 | $59,172,000 | $-53,295,000 | $-86,848,000 |
| Cash Flow From Continuing Investing Activities | $-109,127,000 | $59,172,000 | $-53,296,000 | $-86,848,000 |
| Net Other Investing Changes | $-10,000,000 | $-7,745,000 | $-5,513,000 | $-3,000,000 |
| Capital Expenditure Reported | $0 | $-89,000 | $-331,000 | $-251,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $-6,635,000 | $0 | - | - |
| Issuance Of Capital Stock | $258,128,000 | $0 | $0 | $600,000 |
| Financing Cash Flow | $269,481,000 | $5,374,000 | $-8,355,000 | $20,785,000 |
| Cash Flow From Continuing Financing Activities | $269,481,000 | $5,374,000 | $-8,355,000 | $20,785,000 |
| Net Other Financing Charges | $-13,952,000 | $-161,000 | $-8,560,000 | $2,891,000 |
| Net Common Stock Issuance | $251,493,000 | $0 | - | $0 |
| Common Stock Issuance | $258,128,000 | $0 | - | $0 |
| Net Preferred Stock Issuance | - | - | $0 | $600,000 |
| Preferred Stock Issuance | - | - | $0 | $600,000 |
| Other | ||||
| Issuance Of Debt | $0 | $5,000,000 | $0 | $15,000,000 |
| Interest Paid Supplemental Data | $793,000 | $2,159,000 | $1,923,000 | - |
| Income Tax Paid Supplemental Data | $589,000 | $411,000 | $1,475,000 | - |
| End Cash Position | $85,300,000 | $27,505,000 | $45,034,000 | $190,613,000 |
| Beginning Cash Position | $27,505,000 | $45,034,000 | $190,613,000 | $362,266,000 |
| Effect Of Exchange Rate Changes | $116,000 | $362,000 | $189,000 | $-1,123,000 |
| Changes In Cash | $57,679,000 | $-17,891,000 | $-145,768,000 | $-170,530,000 |
| Proceeds From Stock Option Exercised | $31,940,000 | $535,000 | $205,000 | $2,294,000 |
| Common Stock Payments | $-6,635,000 | $0 | - | - |
| Net Issuance Payments Of Debt | $0 | $5,000,000 | $0 | $15,000,000 |
| Net Long Term Debt Issuance | $0 | $5,000,000 | $0 | $15,000,000 |
| Long Term Debt Issuance | $0 | $5,000,000 | $0 | $15,000,000 |
| Net Investment Purchase And Sale | $-92,895,000 | $66,653,000 | $-46,749,000 | $-82,824,000 |
| Sale Of Investment | $9,050,000 | $81,653,000 | $139,469,000 | $226,834,000 |
| Purchase Of Investment | $-101,945,000 | $-15,000,000 | $-186,218,000 | $-309,658,000 |
| Net Business Purchase And Sale | $4,636,000 | $359,000 | $-443,000 | $0 |
| Sale Of Business | $4,636,000 | $359,000 | $0 | - |
| Net Intangibles Purchase And Sale | $-9,967,000 | $0 | $0 | - |
| Purchase Of Intangibles | $-9,967,000 | $0 | $0 | - |
| Net PPE Purchase And Sale | $-901,000 | $-6,000 | $-259,000 | $-773,000 |
| Purchase Of PPE | $-901,000 | $-6,000 | $-259,000 | $-773,000 |
| Change In Working Capital | $-6,475,000 | $-9,200,000 | $7,469,000 | $-3,335,000 |
| Change In Other Working Capital | $766,000 | $721,000 | - | - |
| Change In Payables And Accrued Expense | $-7,932,000 | $-8,830,000 | $-1,194,000 | $-1,813,000 |
| Change In Accrued Expense | $-6,237,000 | $-6,958,000 | $-3,332,000 | $1,221,000 |
| Change In Payable | $-1,695,000 | $-1,872,000 | $2,138,000 | $-3,034,000 |
| Change In Account Payable | $-1,695,000 | $-1,872,000 | $2,138,000 | $-3,034,000 |
| Change In Prepaid Assets | $691,000 | $-1,091,000 | $8,663,000 | $-1,522,000 |
| Other Non Cash Items | $26,810,000 | $44,543,000 | $-86,336,000 | $-1,756,000 |
| Stock Based Compensation | $14,213,000 | $25,490,000 | $32,982,000 | $42,375,000 |
| Unrealized Gain Loss On Investment Securities | $0 | $2,075,000 | $0 | $-272,000 |
| Asset Impairment Charge | $33,000 | $3,579,000 | $1,011,000 | $852,000 |
| Depreciation Amortization Depletion | $1,012,000 | $473,000 | $319,000 | $168,000 |
| Depreciation And Amortization | $1,012,000 | $473,000 | $319,000 | $168,000 |
| Earnings Losses From Equity Investments | $0 | $2,000,000 | $3,593,000 | $16,006,000 |
| Gain Loss On Investment Securities | $527,563,000 | $-1,260,000 | - | $-336,000 |
| Net Foreign Currency Exchange Gain Loss | $-2,024,000 | $1,078,000 | $799,000 | $-4,950,000 |
| Gain Loss On Sale Of PPE | $692,000 | $0 | - | - |
| Gain Loss On Sale Of Business | $-6,902,000 | $-1,166,000 | $-60,000 | $-1,484,000 |
| Net Income From Continuing Operations | $-660,147,000 | $-150,049,000 | $-43,895,000 | $-157,417,000 |
| Purchase Of Business | - | $0 | $-443,000 | $0 |
| Deferred Tax | - | - | $0 | $5,074,000 |
| Deferred Income Tax | - | - | $0 | $5,074,000 |
Fetched: 2026-08-18